logo image
search icon
Bispecific Antibody Therapeutics Contract Manufacturing Market

Bispecific Antibody Therapeutics Contract Manufacturing Market Size, Share & Trends Analysis Report By Indication (Cancer, Infectious Diseases, Autoinflammatory And Autoimmune Diseases, CNS Conditions, And Others), By Route Of Administration, By End-Users, Region, And Segment Forecasts, 2023-2031

Report ID : 1996 | Published : 2023-08-24 | Pages: 180 | Format: PDF/EXCEL

The Bispecific Antibody Therapeutics Contract Manufacturing Market Size is valued at US$ 5.39 Bn in 2022 and is predicted to reach US$ 82.85 Bn by the year 2031 at an 35.6% CAGR during the forecast period for 2023-2031.

Bispecific Antibody Therapeutics Contract Manufacturing Market

Bispecific antibodies are highly preferred in therapeutic approaches. These antibody therapeutics provide many therapeutic benefits and help meet the patient's unmet needs. In addition, the therapeutic potential to treat cancer, diabetes, Alzheimer's, and ophthalmological diseases drive the market demand. Great interest and investment in bispecific antibodies are essential to business growth. 

Furthermore, growing research in drug discovery, rising clinical trials for antibody therapeutics, high cancer burden worldwide, surging demand for advanced therapeutics, and increasing R&D activities to develop novel therapies are anticipated to produce lucrative growth opportunities in this market over the coming years. 

Competitive Landscape:

Some of the Key Players in the Bispecific Antibody Therapeutics Contract Manufacturing Market:

  • Lonza
  • Roche's
  • Creative Biolabs
  • AbbVie
  • Amgen
  • Janssen
  • Johnson & Johnson
  • IQVIA
  • WuXi Biologicsb b
  • Sino Biological Inc.
  • Other Prominent Players

Market Segmentation:

The Bispecific Antibody Therapeutics Contract Manufacturing Market is segmented based on indication, route of administration, and end-users. The indication segment comprises cancer, infectious diseases, autoinflammatory and autoimmune diseases, and CNS conditions. The market is classified into intravenous, subcutaneous, and others by route of administration. End-users categorize the market into pharmaceutical companies, biopharmaceutical companies, and others.

Cancer Is Expected To Drive The Bispecific Antibody Therapeutics Contract Manufacturing Market In The Upcoming Years

By indication, the cancer segment accounted for the most increased revenue share in 2022. The increased demand for bispecific antibody therapeutics and rising cancer cases globally drive this segment. Similarly, due to its safety and efficacy profile, the bispecific antibody therapeutics contract manufacturing market has become an attractive choice for treating cancer.

The Intravenous Segment Is Growing At The Highest Rate In The Bispecific Antibody Therapeutics Contract Manufacturing Market

Based on the route of administration, the intravenous segment recorded the largest revenue share in 2022. Intravenous antibodies have many advantages in cancer recovery. These antibody therapeutics via IV help the immune system to fight and kill cancer cells more effectively.

Biopharmaceutical Companies Dominated The Market In 2022

By end-users, the biopharmaceutical companies segment dominated the bispecific antibody therapeutics contract manufacturing market in 2022. The increasing demand for advanced antibody therapies, the high prevalence of cancer, and growing R&D investments are responsible for driving the growth of the biopharmaceutical companies and market.

Regionally, North America Led The Bispecific Antibody Therapeutics Contract Manufacturing Market In 2022

North America Bispecific Antibody Therapeutics Contract Manufacturing Market dominated in 2022 and is estimated to continue its trend over 2023-2031. Characteristics such as the growing demand for innovative antibody therapies, increased prevalence of cancer, increasing mergers and acquisitions among companies, rising R&D activities, increasing government investments for clinical research and the growing number of clinical trials contribute to the market growth.

Bispecific Antibody Therapeutics Contract Manufacturing Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2022

USD 5.39 Bn

Revenue Forecast In 2031

USD 82.85 Bn

Growth Rate CAGR

CAGR of 35.6 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Indication, By Route of Administration, By End-users

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Lonza, Roche's, Creative Biolabs, AbbVie, Amgen, Janssen, Johnson & Johnson, IQVIA, WuXi Biologics, Sino Biological Inc., and Others.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Snapshot

Chapter 4. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact Analysis

Chapter 5. Market Segmentation 1: By Indication Estimates & Trend Analysis
5.1. By Indication & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Indication:

5.2.1. Cancer
5.2.2. Infectious Diseases
5.2.3. Autoinflammatory and autoimmune diseases
5.2.4. CNS Conditions
5.2.5. Others

Chapter 6. Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Indication & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Route of Administration:

6.2.1. Intravenous
6.2.2. Subcutaneous
6.2.3. Others

Chapter 7. Market Segmentation 3: By End-users Estimates & Trend Analysis
7.1. By Indication & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By End-users:

7.2.1. Pharmaceutical Companies
7.2.2. Biopharmaceutical Companies
7.2.3. Others

Chapter 8. Bispecific Antibody Therapeutics Contract Manufacturing Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031
8.1.2. North America Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031
8.1.3. North America Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By End-users, 2019-2031
8.1.4. North America Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By country, 2019-2031

8.1.4.1. U.S.
8.1.4.2. Canada

8.2. Europe

8.2.1. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) By Indication, 2019-2031
8.2.2. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031
8.2.3. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By End-users, 2019-2031
8.2.4. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) By country, 2019-2031

8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe

8.3. Asia Pacific

8.3.1. Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) By Indication, 2019-2031
8.3.2. Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031
8.3.3. Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By End-users, 2019-2031
8.3.4. Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) By country, 2019-2031

8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific

8.4. Latin America

8.4.1. Latin America Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) By Indication, 2019-2031
8.4.2. Latin America Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031
8.4.3. Latin America Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By End-users, 2019-2031
8.4.4. Latin America Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) By country, (US$ Million) 2019-2031

8.4.4.1. Brazil
8.4.4.2. Rest of Latin America

8.5. Middle East & Africa

8.5.1. Middle East & Africa Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) By Indication, (US$ Million)
8.5.2. Middle East & Africa Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031
8.5.3. Middle East & Africa Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) estimates and forecasts By End-users, 2019-2031

8.5.4. Middle East & Africa Bispecific Antibody Therapeutics Contract Manufacturing Market revenue (US$ Million) By country, (US$ Million) 2019-2031

8.5.4.1. South Africa
8.5.4.2. GCC Countries
8.5.4.3. Rest of MEA

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles
9.2.1. Lonza
9.2.2. Roche's
9.2.3. Creative Biolabs
9.2.4. AbbVie
9.2.5. Amgen
9.2.6. Janssen
9.2.7. Johnson & Johnson
9.2.8. IQVIA
9.2.9. WuXi Biologicsb b
9.2.10. Sino Biological Inc.
9.2.11. Other Prominent Players

Segmentation of Bispecific Antibody Therapeutics Contract Manufacturing Market

Bispecific Antibody Therapeutics Contract Manufacturing Market By Indication-

  • Cancer
  • Infectious Diseases;
  • Autoinflammatory and autoimmune diseases
  • CNS Conditions
  • Others

Bispecific Antibody Therapeutics Contract Manufacturing Market

Bispecific Antibody Therapeutics Contract Manufacturing Market By Route of Administration-

  • Intravenous
  • Subcutaneous
  • Others

Bispecific Antibody Therapeutics Contract Manufacturing Market By End-users-

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others

Bispecific Antibody Therapeutics Contract Manufacturing Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Bispecific Antibody Therapeutics Contract Manufacturing Market?

Bispecific Antibody Therapeutics Contract Manufacturing Market expected to grow at a 35.6% CAGR during the forecast period for 2023-2031

Lonza, Roche's, Creative Biolabs, AbbVie, Amgen, Janssen, Johnson & Johnson, IQVIA, WuXi Biologics, Sino Biological Inc., and Others

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Biotechnology

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach